Shares of Intrexon Corporation (NYSE:XON) shot up 6.5% on Tuesday . The company traded as high as $12.84 and last traded at $12.58. 7,219,600 shares traded hands during mid-day trading, an increase of 550% from the average session volume of 1,110,684 shares. The stock had previously closed at $11.81.
A number of research firms have recently weighed in on XON. Bank of America Corporation cut their price objective on shares of Intrexon Corporation from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday. Stifel Nicolaus increased their price objective on shares of Intrexon Corporation from $39.00 to $57.00 and gave the stock a “buy” rating in a research note on Friday. Northland Securities reissued a “buy” rating and set a $21.00 price target on shares of Intrexon Corporation in a report on Friday. BidaskClub downgraded shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Finally, JMP Securities reissued an “outperform” rating and set a $42.00 price target on shares of Intrexon Corporation in a report on Thursday, October 5th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $38.50.
The company has a quick ratio of 1.85, a current ratio of 2.05 and a debt-to-equity ratio of 0.01.
Institutional investors and hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC lifted its holdings in Intrexon Corporation by 2,031.7% during the second quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 4,937 shares in the last quarter. SG Americas Securities LLC purchased a new position in Intrexon Corporation during the third quarter valued at $139,000. Federated Investors Inc. PA purchased a new position in Intrexon Corporation during the second quarter valued at $172,000. Quantbot Technologies LP lifted its holdings in Intrexon Corporation by 423.7% during the third quarter. Quantbot Technologies LP now owns 9,993 shares of the biotechnology company’s stock valued at $189,000 after purchasing an additional 8,085 shares in the last quarter. Finally, John G Ullman & Associates Inc. acquired a new stake in shares of Intrexon Corporation in the second quarter valued at about $212,000. 77.28% of the stock is currently owned by institutional investors and hedge funds.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.